Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Patrocinadores

Patrocinador principal: Rabin Medical Center

Colaborador: The Israeli Society for Pediatric Hematology-Oncology
International BFM Study Group

Fuente Rabin Medical Center
Resumen breve

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. There have been isolated case reports of patients with childhood ALL who developed LPD after ALL diagnosis, without undergoing stem cell transplantation, but data regarding such cases are limited. We propose here an international collaboration, to form a comprehensive database of children who developed LPD after diagnosis of acute lymphoblastic leukemia/lymphoma

Descripción detallada

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. These disorders have been extensively described in the post-transplant setting, ie after hematopoietic stem cell (SCT) or solid organ (SOT) transplant. However, since the 1980's, there have been isolated case reports of patients with childhood ALL, who developed LPD after diagnosis of ALL, without undergoing SCT. Comprehensive information is unavailable regarding the prevalence, clinical manifestations, treatment, outcome and pathogenesis of such disorders in this setting. We propose here an international collaboration, to form a comprehensive database of children who developed LPD during the treatment of acute lymphoblastic leukemia/lymphoma (ALL/LBL).

Information will be collected in a de-identified fashion regarding patient characteristics, leukemia and LPD characteristics, treatment and outcome. The aims of this retrospective study are:

1. To build a database of children who developed LPD after diagnosis of ALL/LBL

2. To investigate the characteristics and outcome of this disorder

Estado general Recruiting
Fecha de inicio August 25, 2019
Fecha de Terminación March 18, 2022
Fecha de finalización primaria December 18, 2021
Tipo de estudio Observational
Resultado primario
Medida Periodo de tiempo
Probability of survival 1 year
Resultado secundario
Medida Periodo de tiempo
Event-free survival 5 years
Inscripción 40
Condición
Elegibilidad

Método de muestreo: Non-Probability Sample

Criterios:

Inclusion Criteria:

- Children and young adults treated for acute lymphoblasticleukemia/lymphoma who developed LPD after ALL/LBL diagnosis

Exclusion Criteria:

- age>30 years

Género: All

Edad mínima: N/A

Edad máxima: 30 Years

Voluntarios Saludables: No

Oficial general
Apellido Papel Afiliación
Sarah Elitzur, MD Principal Investigator Schneider Children's Medical Center
Contacto general

Apellido: Sarah Elitzur, MD

Teléfono: 97239253669

Email: [email protected]

Ubicación
Instalaciones: Estado: Contacto: Copia de seguridad de contactos:
Schneider Children's Medical Center | Petah Tikva, 4920235, Israel Recruiting Sarah Elitzur, MD 97239253669 [email protected]
Schneider Children's Medical Center | Petah Tikva, 4920235, Israel Recruiting Sarah Elitzur, MD [email protected]
Ubicacion Paises

Israel

Fecha de verificación

August 2019

Fiesta responsable

Tipo: Sponsor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Datos del paciente Undecided
Información de diseño del estudio

Modelo de observación: Cohort

Perspectiva de tiempo: Retrospective

Fuente: ClinicalTrials.gov